SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (509)2/2/2000 2:10:00 PM
From: biowa  Read Replies (2) of 666
 
V1,

Additional bad news for IDPH

That's where I would put the movement today, on the Zev delay, not the patent issue. Not sure if CLTR should pursue infringement in the courts; waste of time, money, etc. on a product that if data is correct should be inferior to Bexxar and that IDPH won't promote for first-line use. If there is a patent issue.

Now, one of the things I do find interesting in the ,547 patent is the relatively detailed arguments about why dosimetry DOES matter. Could be that not only will Bex BLA get filed 6 or more months earlier, but that Zev could face some tough analysis on the dosimetry issue.

biowa
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News